Rich Pharmaceuticals Inc., of Beverly Hills, Calif., said it filed its submission package to the institutional review board of Phramongkutklao Hospital in Bangkok, Thailand, as part of a process that will lead to a study for the treatment of acute myelocytic leukemia in refractory patients in a phase I/II trial.